Výsledky vyhledávání

Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States

Autor: Ronda Copher, Arianna Kee, Aaron Gerds

Publikováno v: The Oncologist. 27:228-235

Background This study analyses treatment patterns, health care resource utilization (HCRU), and costs in patients with myelofibrosis (MF) and a subgroup treated with ruxolitinib (RUX). Materials and Methods Treatment patterns, all-cause and MF-relate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61453f27c6a40abe3e4f4919cb22b8df
https://doi.org/10.1093/oncolo/oyab058

Zobrazit plný text záznamu

Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy

Autor: Rina Mehta, Leorah Freeman, Arianna Kee, Marc Tian

Publikováno v: Drugs-Real World Outcomes

Background Real-world studies of disease-modifying therapies (DMTs) in multiple sclerosis (MS) have reported suboptimal adherence. Objective We aimed to describe treatment patterns, relapses, healthcare resource utilization, and costs in MS patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03bdfc01ed05da100fd3ae74a9dfa641
http://europepmc.org/articles/PMC8605953

Zobrazit plný text záznamu

Evaluating Treatment Patterns, Relapses, Healthcare Resource Utilization, and Costs Associated with Disease-Modifying Treatments for Multiple Sclerosis in DMT-Naïve Patients

Autor: Leorah Freeman, Marc Tian, Rina Mehta, Arianna Kee

Publikováno v: ClinicoEconomics and Outcomes Research: CEOR

Leorah Freeman,1 Arianna Kee,2 Marc Tian,2 Rina Mehta2 1Dell Medical School, The University of Texas at Austin, TX, USA; 2Bristol Myers Squibb, Princeton, NJ, USACorrespondence: Leorah FreemanHealth Discovery Building, Dell Medical School, The Univer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efbff6b9ed4da64fda6781a18182fd11
https://www.dovepress.com/evaluating-treatment-patterns-relapses-healthcare-resource-utilization-peer-reviewed-article-CEOR

Zobrazit plný text záznamu

Real-World Utilization of Fedratinib for Myelofibrosis Post-Ruxolitinib: Patient Characteristics, Treatment Patterns, and Characterization of Ruxolitinib Failure

Autor: Bruce A. Feinberg, Pranav Abraham, Djibril Liassou, John Mascarenhas, Claire N. Harrison, Alexandrina Balanean, Jonathan Kish, Aaron T. Gerds, Arianna Kee, Ali McBride, Jose Alberto Nadal

Publikováno v: Blood. 138:3059-3059

Introduction: In August 2019, fedratinib (FEDR) became the second treatment (in addition to ruxolitinib [RUX]) to be approved for intermediate- or high-risk primary or secondary myelofibrosis (MF). No real-world data (RWD) have been presented on demo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::306b5bb947cb5574c69279ee9c9df220
https://doi.org/10.1182/blood-2021-145569

Zobrazit plný text záznamu

Dasatinib Treatment Patterns after Pleural Effusion Among Patients with Chronic Myeloid Leukemia

Autor: John Brokars, Arianna Kee, Ali McBride, Sheila R. Reddy, Eunice Chang, Marian H. Tarbox, Thomas W. LeBlanc

Publikováno v: Blood. 138:3607-3607

Introduction Decision-making in the treatment (Tx) of chronic myeloid leukemia (CML) is complex and dependent on many factors, including disease phase and drug tolerability. The tyrosine kinase inhibitor (TKI) dasatinib is an effective long-term Tx o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d95095e115f13ba84bd6d70cb06cb488
https://doi.org/10.1182/blood-2021-145456

Zobrazit plný text záznamu

Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

Autor: John Mascarenhas, Jonathan Kish, Arianna Kee, Ali McBride, Jose Alberto Nadal, Djibril Liassou, Aaron T. Gerds, Pranav Abraham, Bruce A. Feinberg, Claire N. Harrison, Alexandrina Balanean

Publikováno v: Blood. 138:1980-1980

Introduction: Relief of symptoms and splenomegaly is an important treatment goal for all patients with myelofibrosis (MF). In August 2019, fedratinib (FEDR) became the second treatment to be approved for intermediate- or high-risk primary or secondar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d1809bdc6208e60c2aa6ac66bf46bab
https://doi.org/10.1182/blood-2021-145573

Zobrazit plný text záznamu

Comparative Effectiveness of Fedratinib and Pacritinib for the Treatment of Myelofibrosis in Patients with Low Platelet Counts: A Simulated Treatment Comparison Study

Autor: Shelonitda Rose, Gabriel Tremblay, Pranav Abraham, Patrick Daniele, Arianna Kee, Ali McBride

Publikováno v: Blood. 138:5034-5034

Introduction: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm with an estimated prevalence of 4-6/100,000 persons in the USA. Patients with MF experience aberrant hematopoiesis, bone marrow fibrosis, splenomegaly,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc7a08ef15016e67677ff0d222b530f5
https://doi.org/10.1182/blood-2021-145685

Zobrazit plný text záznamu

P-214: Sequencing of treatment regimens after lenalidomide (LEN) in patients with multiple myeloma (MM) in a US community oncology setting

Autor: Alisha Monnette, Chuck Wentworth, Robert M. Rifkin, Arianna Kee

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S157

Background Choice of treatment and sequencing of MM therapies is complex with multiple therapeutic options. LEN-containing regimens are a standard of care at induction, but there is a lack of consensus on the most appropriate therapy for patients (pt

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b406f094593db406fd8df0d3756212de
https://doi.org/10.1016/s2152-2650(21)02341-7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání